NN is a diversified industrial company that manufactures high precision bearing components, industrial plastic products, and precision metal components. The Company manufactures and sells precision steel balls and rollers and precision metal retainers for roller bearings. It also manufactures a range of components, assemblies, and instruments for the medical end market, electrical contacts, assemblies and precision stampings for the electrical control end market, the automotive end market, and various engineered materials for the aerospace and defense end market. In addition, the Company manufactures and sells precision plastic retainers and various specialized plastic products. Further, it offers precision-machined metal components and subassemblies for the consumer transportation, industrial technology, HVAC, fluid power, and diesel engine end markets.

Company Growth (employees)
Johnson City, US
Size (employees)
4,730 (est)
NN was founded in 1980 and is headquartered in Johnson City, US

NN Office Locations

NN has offices in Johnson City, Kentwood, Attleboro, Naucalpan de Juárez and in 5 other locations
Johnson City, US (HQ)
207 Mockingbird Ln
Attleboro, US
110 Frank Mossberg Drive
Kentwood, US
4180 40th Street SE
Boituva, BR
Rodovia Boituva-Porto Feliz km 12, 1230
Foshan, CN
7 Xinyue Road, Bldg. 6 Shunde Industrial Park Wusha Daliang, Shunde District
Naucalpan de Juárez, MX
Av. San Luis Tlatilco 42 Parque Industrial
Show all (9)

NN Financials and Metrics

NN Financials

NN's revenue was reported to be $833.5 m in FY, 2016

Revenue (Q3, 2017)

148.2 m

Gross profit (Q3, 2017)

37.3 m

Gross profit margin (Q3, 2017), %


Net income (Q3, 2017)

132.9 m

EBIT (Q3, 2017)

6.3 m

Market capitalization (16-Feb-2018)

687.2 m

Cash (30-Sep-2017)

347.4 m


1.1 b
NN's current market capitalization is $687.2 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016


373.2 m488.6 m667.3 m833.5 m

Revenue growth, %


Cost of goods sold

526 m621 m

Gross profit

141.3 m212.5 m
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017


93 m102.5 m106.7 m125.6 m163.7 m164.9 m154.8 m212.2 m214.3 m205 m226.3 m225.9 m148.2 m

Cost of goods sold

73 m80.3 m84.3 m100.4 m129.3 m128.7 m120.2 m159.8 m156.8 m152.5 m167 m166 m110.8 m

Gross profit

20 m22.2 m22.4 m25.2 m34.4 m36.1 m34.6 m52.5 m57.5 m52.4 m59.4 m59.8 m37.3 m

Gross profit Margin, %

USDY, 2009Y, 2010Y, 2011Y, 2012Y, 2013Y, 2014Y, 2015FY, 2016


8.7 m5.6 m4.5 m19 m3 m37.3 m15.1 m14.4 m

Accounts Receivable

58.9 m97.5 m123 m139.5 m


54.5 m91.5 m119.8 m114.9 m

Current Assets

125.7 m242.8 m280.2 m280.6 m
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017


4.5 m4.5 m5.8 m26.9 m16.8 m21.4 m40.1 m15.1 m15.1 m14.8 m19.6 m19.2 m347.4 m

Accounts Receivable

117.2 m114.8 m108.1 m143.3 m147.1 m147.4 m159.6 m162.4 m108.2 m


48.1 m57.4 m61.5 m86.9 m85.6 m87.9 m92.6 m120.1 m118.8 m118.8 m116.6 m123.7 m76.6 m

Current Assets

126.8 m146.4 m158 m246.7 m238 m240.7 m258.4 m295.6 m297.9 m295.5 m310.3 m327.6 m552.4 m
    USDFY, 2013FY, 2014FY, 2015FY, 2016

    Net Income

    17.2 m8.2 m(7.4 m)7.9 m

    Depreciation and Amortization

    17 m22.1 m44.5 m62.5 m

    Accounts Receivable

    (6.3 m)(3.3 m)(806 k)(18.5 m)


    (7.2 m)(9.8 m)(1.8 m)4.4 m
    USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q3, 2017

    Net Income

    5.1 m5.2 m5.2 m(3.8 m)6 m7 m4.6 m(1.3 m)2 m4.1 m7.4 m132.9 m

    Depreciation and Amortization

    4.1 m3.9 m4.1 m5.9 m8.5 m8.6 m8.6 m17.3 m15.1 m14.7 m15.6 m

    Accounts Receivable

    114.8 m108.1 m143.3 m147.1 m147.4 m159.6 m108.2 m


    87.9 m92.6 m120.1 m118.8 m118.8 m116.6 m76.6 m
      USDY, 2017


      180.1 x


      31.3 k


      1.8 x


      0.5 x

      Financial Leverage

      3.4 x
      Show all financial metrics

      NN Market Value History

      NN's Web-traffic and Trends

      NN Online and Social Media Presence

      NN News and Updates

      Parcom Capital buys Viroclinics

      Parcom Capital said Aug. 29 that it has acquired Viroclinics Biosciences. Financial terms weren’t announced. Viroclinics, of the Netherlands, tests new vaccines and drugs in the clinical trial stages prior to their market launch.

      NN Company Life and Culture

      You may also be interested in